SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans

D. T. Purtilo, K. Falk, S. J. Pirruccello, H. Nakamine, K. Kleveland, J. R. Davis, M. Okano, Y. Taguchi, W. G. Sanger, Kirk Beisel

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Immunodeficient humans are at very high risk of developing Epstein-Barr virus (EBV)-induced lymphomagenesis. Severe combined immunodeficient mice (SCID) have been shown to develop lymphoproliferative disease (LPD) following transfer of peripheral blood leukocytes (PBL) with latent EBV. To study mechanisms of lymphomagenesis, we compared results of engraftment of PBL from normal donors and immunodeficient donors with X-linked lymphoproliferative disease (XLP). Graft-versus-host disase (GVHD) developed in 6 of 10 SCID mice 4 to 8 weeks following transfer of PBL from normal donors. In contrast, none of 9 mice engrafted with PBL from XLP patients with T-cell defects showed GVHD. LPD developed in mice regardless of the immune competence of the donors. The expression of EBV-encoded proteins, results of immunophenotyping, and karyotyping of the LPD lesions revealed lethal oligoclonal LPD owing to transfer of latent EBV in B cells in mice engrafted with PBL from seropositive donors. Polyclonal LPD developed in mice engrafted with PBL from seronegative patients which were infected with B95-8 virus 6 weeks after transfer of the cells. This model is useful for investigating mechanisms of EBV-induced LPD in immunodeficient patients.

Original languageEnglish
Pages (from-to)510-517
Number of pages8
JournalInternational Journal of Cancer
Volume47
Issue number4
StatePublished - 1991
Externally publishedYes

Fingerprint

SCID Mice
Human Herpesvirus 4
Leukocytes
Tissue Donors
Lymphoproliferative Disorders
Transplants
Immunophenotyping
Karyotyping
Mental Competency
B-Lymphocytes
Viruses
T-Lymphocytes
Proteins

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Purtilo, D. T., Falk, K., Pirruccello, S. J., Nakamine, H., Kleveland, K., Davis, J. R., ... Beisel, K. (1991). SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans. International Journal of Cancer, 47(4), 510-517.

SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans. / Purtilo, D. T.; Falk, K.; Pirruccello, S. J.; Nakamine, H.; Kleveland, K.; Davis, J. R.; Okano, M.; Taguchi, Y.; Sanger, W. G.; Beisel, Kirk.

In: International Journal of Cancer, Vol. 47, No. 4, 1991, p. 510-517.

Research output: Contribution to journalArticle

Purtilo, DT, Falk, K, Pirruccello, SJ, Nakamine, H, Kleveland, K, Davis, JR, Okano, M, Taguchi, Y, Sanger, WG & Beisel, K 1991, 'SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans', International Journal of Cancer, vol. 47, no. 4, pp. 510-517.
Purtilo DT, Falk K, Pirruccello SJ, Nakamine H, Kleveland K, Davis JR et al. SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans. International Journal of Cancer. 1991;47(4):510-517.
Purtilo, D. T. ; Falk, K. ; Pirruccello, S. J. ; Nakamine, H. ; Kleveland, K. ; Davis, J. R. ; Okano, M. ; Taguchi, Y. ; Sanger, W. G. ; Beisel, Kirk. / SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans. In: International Journal of Cancer. 1991 ; Vol. 47, No. 4. pp. 510-517.
@article{48f4451787494d5f90f9c360a343602b,
title = "SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans",
abstract = "Immunodeficient humans are at very high risk of developing Epstein-Barr virus (EBV)-induced lymphomagenesis. Severe combined immunodeficient mice (SCID) have been shown to develop lymphoproliferative disease (LPD) following transfer of peripheral blood leukocytes (PBL) with latent EBV. To study mechanisms of lymphomagenesis, we compared results of engraftment of PBL from normal donors and immunodeficient donors with X-linked lymphoproliferative disease (XLP). Graft-versus-host disase (GVHD) developed in 6 of 10 SCID mice 4 to 8 weeks following transfer of PBL from normal donors. In contrast, none of 9 mice engrafted with PBL from XLP patients with T-cell defects showed GVHD. LPD developed in mice regardless of the immune competence of the donors. The expression of EBV-encoded proteins, results of immunophenotyping, and karyotyping of the LPD lesions revealed lethal oligoclonal LPD owing to transfer of latent EBV in B cells in mice engrafted with PBL from seropositive donors. Polyclonal LPD developed in mice engrafted with PBL from seronegative patients which were infected with B95-8 virus 6 weeks after transfer of the cells. This model is useful for investigating mechanisms of EBV-induced LPD in immunodeficient patients.",
author = "Purtilo, {D. T.} and K. Falk and Pirruccello, {S. J.} and H. Nakamine and K. Kleveland and Davis, {J. R.} and M. Okano and Y. Taguchi and Sanger, {W. G.} and Kirk Beisel",
year = "1991",
language = "English",
volume = "47",
pages = "510--517",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - SCID mouse model of Epstein-Barr virus-induced lymphomagenesis of immunodeficient humans

AU - Purtilo, D. T.

AU - Falk, K.

AU - Pirruccello, S. J.

AU - Nakamine, H.

AU - Kleveland, K.

AU - Davis, J. R.

AU - Okano, M.

AU - Taguchi, Y.

AU - Sanger, W. G.

AU - Beisel, Kirk

PY - 1991

Y1 - 1991

N2 - Immunodeficient humans are at very high risk of developing Epstein-Barr virus (EBV)-induced lymphomagenesis. Severe combined immunodeficient mice (SCID) have been shown to develop lymphoproliferative disease (LPD) following transfer of peripheral blood leukocytes (PBL) with latent EBV. To study mechanisms of lymphomagenesis, we compared results of engraftment of PBL from normal donors and immunodeficient donors with X-linked lymphoproliferative disease (XLP). Graft-versus-host disase (GVHD) developed in 6 of 10 SCID mice 4 to 8 weeks following transfer of PBL from normal donors. In contrast, none of 9 mice engrafted with PBL from XLP patients with T-cell defects showed GVHD. LPD developed in mice regardless of the immune competence of the donors. The expression of EBV-encoded proteins, results of immunophenotyping, and karyotyping of the LPD lesions revealed lethal oligoclonal LPD owing to transfer of latent EBV in B cells in mice engrafted with PBL from seropositive donors. Polyclonal LPD developed in mice engrafted with PBL from seronegative patients which were infected with B95-8 virus 6 weeks after transfer of the cells. This model is useful for investigating mechanisms of EBV-induced LPD in immunodeficient patients.

AB - Immunodeficient humans are at very high risk of developing Epstein-Barr virus (EBV)-induced lymphomagenesis. Severe combined immunodeficient mice (SCID) have been shown to develop lymphoproliferative disease (LPD) following transfer of peripheral blood leukocytes (PBL) with latent EBV. To study mechanisms of lymphomagenesis, we compared results of engraftment of PBL from normal donors and immunodeficient donors with X-linked lymphoproliferative disease (XLP). Graft-versus-host disase (GVHD) developed in 6 of 10 SCID mice 4 to 8 weeks following transfer of PBL from normal donors. In contrast, none of 9 mice engrafted with PBL from XLP patients with T-cell defects showed GVHD. LPD developed in mice regardless of the immune competence of the donors. The expression of EBV-encoded proteins, results of immunophenotyping, and karyotyping of the LPD lesions revealed lethal oligoclonal LPD owing to transfer of latent EBV in B cells in mice engrafted with PBL from seropositive donors. Polyclonal LPD developed in mice engrafted with PBL from seronegative patients which were infected with B95-8 virus 6 weeks after transfer of the cells. This model is useful for investigating mechanisms of EBV-induced LPD in immunodeficient patients.

UR - http://www.scopus.com/inward/record.url?scp=0026083257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026083257&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 510

EP - 517

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -